NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
09/09/2025
Voltar para busca
Dado oficial do USPTO
KAZIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
10/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
26/09/2017
Data de registro
04/12/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/09/2025
Última transação
10/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Sydney, NSW, AU
Examinador
FLETCHER, TRACY
Localização atual
Historical data usage
Titulares e representantes
Titulares
Kazia Therapeutics Limited
Kazia Therapeutics Limited
Representantes
Sana Hakim K&L Gates LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in science; chemicals for use in the manufacture of pharmaceuticals and medicine; biochemicalsprecursors for in vitro genetic engineering use in the field of pharmaceuticals and medicine; chemical preparations for the manufacture of pharmaceuticals; chemicals for use in manufacturing of pharmaceuticals
Classe 5
Pharmaceutical preparationscytotoxic chemotherapy; pharmaceutical preparations for the treatment of cancer; anti-cancer pharmaceutical preparations; pharmaceutical preparations for the diagnosis and treatment of cancer; medicines for human usepharmaceutical compounds for treating cancer; pharmaceutical preparations for treating chemical imbalances; diagnostic preparations for medical purposes
Classe 42
Scientific research services; scientific and medical research services; pharmaceutical research services; research relating to pharmaceuticals; research and development of pharmaceuticals; biotechnology research; biochemical and chemical research services; scientific research relating to biology and chemistry; scientific research in the field of pharmacy; scientific research into the development of new products; services for assessing the safety of pharmaceuticalsscientific laboratory services for assessing efficacy of pharmaceuticals; scientific research services featuring the preparation of reports thereon; medical analytical laboratory services; laboratory research and analysis in the field of pharmaceuticals; laboratory research and analysis in the field of cancer treatments; development of products; development of new products; development of pharmaceutical preparations for the diagnosis and treatment of cancer; advisory services relating to scientific research; consultancy and information services relating to the aforementioned services
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
71AG
REGISTERED-SEC.71 ACCEPTED
09/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/09/2025
ES71
TEAS SECTION 71 RECEIVED
03/06/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/06/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/03/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
15/03/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/03/2019
FIMP
FINAL DISPOSITION PROCESSED
11/03/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/03/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/12/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/09/2018
PUBO
PUBLISHED FOR OPPOSITION
18/09/2018
GPNX
NOTIFICATION PROCESSED BY IB
15/09/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/08/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/08/2018
DMCC
DATA MODIFICATION COMPLETED
16/08/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
14/08/2018
ALIE
ASSIGNED TO LIE
14/08/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/08/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
14/08/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/08/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/08/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/08/2018
RFNT
REFUSAL PROCESSED BY IB
24/03/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/03/2018
RFRR
REFUSAL PROCESSED BY MPU
07/03/2018
MAFR
APPLICATION FILING RECEIPT MAILED
02/03/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/03/2018
CNRT
NON-FINAL ACTION WRITTEN
28/02/2018
DOCK
ASSIGNED TO EXAMINER
26/02/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/02/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/02/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KAZIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.